FASLODEXTM
(fulvestrant)

FASLODEXTM is indicated as monotherapy for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

  • Not previously treated with endocrine therapy, or
  • With disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy

Faslodex is also indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

  • In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone agonist.

COMBINATION WITH PALBOCICLIB

Efficacy of FASLODEX in combination with palbociclib in PALOMA-3

Primary endpoint PFS

Treatment with FASLODEX 500 mg in combination with Palbociclib was associated with a 54% reduction in the risk of disease progression compared to treatment with FASLODEX 500 mg alone (HR 0.46; 95% CI 0.36 - 0.59; p<0.00013,4

Median PFS 9.5 months with Faslodex + palbociclib vs 4.6 months with Faslodex + placebo (HR=0.46; 95% CI 0·36–0·59); p<0.0001.3
Median PFS 9.5 months with Faslodex + palbociclib vs 4.6 months with Faslodex + placebo (HR=0.46; 95% CI 0·36–0·59); p<0.0001.3

Adapted from Cristofanilli, M et al. Lancet Oncol. 2016;17(4):425-439.3

FASLODEX in combination with palbociclib showed consistent PFS results across select subgroups3

PFS results were consistent across select subgroups3
PFS results were consistent across select subgroups3

Adapted from Cristofanilli, M et al. Lancet Oncol. 2016;17(4):425-439.3